Browse the evidence

Ultra-processed foods (UPF) contribute to negative health outcomes (obesity, diabetes, CVD, mortality) and environmental impacts, yet are often perceived as healthy due to marketing.

Limit ultra-processed foods, even if they are plant-based. Focus on whole, minimally processed foods for better health and environmental outcomes.

Discontinuation of GLP-1 agonist pharmacotherapy (e.g., semaglutide) leads to rapid weight regain, necessitating indefinite long-term treatment for maintenance.

If you use GLP-1 medications like semaglutide for weight loss, understand that stopping them will likely cause you to regain the weight quickly. These drugs treat obesity as a chronic condition, meaning you likely need to stay on them long-term to keep the weight off, regardless of cost or insurance hurdles.

Obesity (BMI ≥ 25 kg/m²) is a critical, modifiable independent risk factor that drives the bidirectional overlap between asthma and obstructive sleep apnea (OSA) through mechanisms including altered lung mechanics, airway hyperresponsiveness, and adipokine production.

If you have asthma or sleep apnea and carry excess weight, weight management is likely the most impactful single intervention you can make. Losing even a small percentage of body weight can significantly reduce the severity of sleep apnea events and improve asthma control. Focus on sustainable weight loss strategies as a primary treatment adjunct.

Patients who transfer hospitals for secondary MBS are significantly younger, have fewer obesity-related comorbidities (hypertension, GERD), and are more likely to undergo secondary surgery for recurrent weight gain compared to those who stay.

If you are younger and generally healthy but are experiencing weight regain after your first bariatric surgery, you are part of a common group that seeks a second opinion or a different surgeon for revisional surgery. This is often driven by dissatisfaction with the amount of weight lost rather than medical complications.

Newer GLP-1 and dual-agonist obesity medications produce significant weight loss (15-21%) and metabolic benefits, but discontinuation leads to weight regain.

Use GLP-1 medications as a long-term tool for weight management, not a short-term fix. Be prepared to continue treatment to maintain weight loss, as stopping often leads to regain.

Metabolic bariatric surgery is the most effective therapy for severe obesity, providing greater weight loss and mortality reduction than pharmacotherapy.

For severe obesity, surgery offers the highest chance of significant, sustained weight loss and resolution of comorbidities. Discuss eligibility with a bariatric specialist.

GLP-1 analogs (e.g., Semaglutide, Liraglutide) and dual agonists (Tirzepatide) produce significant weight loss (up to 21%) but are associated with high costs, lifelong administration requirements, and gastrointestinal side effects that may drive patients toward complementary therapies.

GLP-1 drugs (Semaglutide, Tirzepatide) are highly effective for weight loss (15-21%), but they are expensive, require lifelong injections, and cause GI side effects. If you experience side effects or cannot afford long-term use, you are not alone; many patients seek complementary therapies like TCM to manage weight and side effects.

In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.

For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.

Bariatric surgery is an effective and durable weight-loss intervention that reduces major adverse liver outcomes (MALO) and cardiovascular events in patients with MASH, though data in advanced cirrhosis is limited.

Bariatric surgery offers significant long-term benefits for liver and heart health in MASH patients. It should be considered for eligible patients, especially when other treatments fail, despite limited data in advanced cirrhosis.

New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.

New GLP-1/GIP medications like semaglutide (2.4mg weekly) and tirzepatide are highly effective, producing 15-25% weight loss over ~1.5 years. This efficacy is now comparable to surgery, making medication a primary, not just secondary, option for obesity treatment.

High body mass index (BMI) and visceral adiposity are strong independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. High body weight puts direct mechanical and hormonal stress on your kidneys, increasing the risk of kidney failure. If you are overweight, even modest weight loss through diet and exercise can significantly lower your risk of developing kidney disease or slow its progression.

SGLT2 inhibitors reduce systemic inflammation and oxidative stress by decreasing body fat mass and improving insulin resistance, which lowers inflammatory markers like IL-6 and TNF-alpha.

By helping you lose weight through sugar excretion, SGLT2 inhibitors reduce the inflammation that damages blood vessels, offering protection beyond just lowering blood sugar.

An intensive lifestyle intervention (diet and exercise) reduces major cardiovascular events in middle-aged women with poorly controlled diabetes and poor subjective health, but shows no benefit for middle-aged/older men with well-controlled diabetes and excellent health.

If you are a middle-aged woman with type 2 diabetes that is not well-controlled and you feel your general health is poor, an intensive lifestyle program focusing on weight loss and exercise is likely to reduce your risk of heart events. However, if you are a man with well-controlled diabetes and feel healthy, this specific intensive approach may not offer cardiovascular protection. Consult your doctor to see if your specific profile matches the 'benefiting' subgroup.

Poor glycemic control exacerbates dyslipidemia in diabetes by increasing hepatic VLDL production and decreasing HDL levels, while improvements in glycemic control can reverse these lipid abnormalities.

For people with diabetes, keeping blood sugar levels in range is important, but it is not enough to protect your heart. Even if your A1C is good, you likely still have abnormal cholesterol levels, specifically high triglycerides and low HDL. This is because diabetes changes how your liver processes fats. You need to monitor your lipid profile separately and likely take medication (like statins) to manage cardiovascular risk, regardless of how well your blood sugar is controlled.

Increasing cardiorespiratory fitness (CRF) reduces morbidity and mortality regardless of changes in body weight or BMI, whereas intentional weight loss in healthy overweight/obese individuals does not improve and may increase mortality risk.

Stop focusing on weight loss as the primary health goal. Instead, aim for 150 minutes of moderate-intensity physical activity per week (like brisk walking or cycling). This level of activity significantly reduces your risk of death and heart disease, regardless of whether you lose weight. Prioritize feeling stronger and more energetic over the number on the scale.

A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.

For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.

Consuming lipids with a higher solid fat content (SFC) and crystalline structure significantly delays postprandial plasma triglyceride (TAG) increases and reduces the total incremental area under the curve compared to compositionally identical liquid lipids.

If you are concerned about post-meal blood fat spikes, the physical form of the fat you eat matters. Solid fats (like those in butter or palm stearin) digest more slowly and may result in lower post-meal triglyceride levels compared to liquid oils (like olive or canola oil), even if they have the same fatty acid makeup. This suggests that food structure and fat state are important levers for metabolic health.

Obesity and overweight status are strongly associated with higher odds of dyslipidemia in Iranian adults, with obese individuals having 2.8 times higher risk compared to normal-weight adults.

Maintaining a healthy weight is crucial for managing blood lipids. In this population, obesity significantly increases the risk of dyslipidemia. Focus on sustainable lifestyle changes including balanced nutrition and regular physical activity to manage weight and improve lipid profiles.

Physical inactivity is associated with increased odds of dyslipidemia, with inappropriate physical activity increasing the odds by 1.2 times compared to appropriate activity.

Regular physical activity helps manage blood lipids. This study found that those with inappropriate physical activity had higher odds of dyslipidemia. Aim for regular moderate-to-vigorous physical activity as part of a healthy lifestyle.

Ultra rapid lispro (URLi) administered as a bolus with basal insulin improves postprandial glucose excursions (PPGE) after breakfast more effectively than standard insulin lispro in adults with type 2 diabetes, while maintaining non-inferior HbA1c reduction and similar safety profiles regarding hypoglycemia and weight gain.

If you have Type 2 Diabetes and struggle with high blood sugar after meals, especially breakfast, ask your doctor about Ultra Rapid Lispro (URLi). It is taken exactly like your current rapid-acting insulin (just before eating) but absorbs faster to better match your food. This can significantly reduce the sharp blood sugar spikes after breakfast without increasing your risk of low blood sugar or weight gain compared to standard insulin lispro.

Higher intake of ultra-processed foods is associated with a significantly increased risk of developing inflammatory bowel disease (IBD), including both Crohn's disease and ulcerative colitis.

To lower your risk of inflammatory bowel disease, focus on reducing ultra-processed foods. This includes soft drinks, refined sweetened foods (candy, pastries), salty snacks, and processed meats. You do not need to avoid natural foods like meat, dairy, or vegetables, as the study found no link between those and IBD risk. The key is minimizing items with additives and preservatives, which may disrupt gut health.

Indian populations have a higher susceptibility to type 2 diabetes at lower body mass indices (BMI) compared to global averages.

If you are of Indian descent, be aware that you may be at risk for diabetes even if you have a normal BMI. Prioritize regular screening and maintain a healthy lifestyle to manage risk factors.

Metformin is the preferred initial oral hypoglycemic monotherapy for type 2 diabetes due to its efficacy, safety, and low risk of hypoglycemia and weight gain.

Start with metformin as your first medication if lifestyle changes alone aren't enough. It is the standard because it works well, is safe long-term, and rarely causes low blood sugar or weight gain. If your blood sugar isn't controlled, your doctor will add another medication.

If metformin is contraindicated or not tolerated, other oral hypoglycemic agents (DPP4 inhibitors, SGLT2 inhibitors, Sulfonylureas, etc.) can be used as initial monotherapy based on clinical situation.

If you can't take metformin, your doctor will choose another medication based on your specific health needs, such as kidney function or heart risk. Options include DPP4 inhibitors, SGLT2 inhibitors, or others.